<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26669">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01806415</url>
  </required_header>
  <id_info>
    <org_study_id>201304126</org_study_id>
    <nct_id>NCT01806415</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers</brief_title>
  <official_title>A Double Blind, Randomized, Single Dose, Placebo Controlled Study of the Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, blinded, parallel group, placebo-controlled trial on 32 evaluable
      healthy male and non-pregnant female, 18-50 year old volunteers.  The investigators goal is
      to observe the pharmacokinetics of fenobam after oral administration of 50, 100 or 150 mg in
      groups of healthy individuals and to compare the side effects and tolerability of a single
      dose of fenobam with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine)
      urea hydrate], oral administration of one 50 mg gelatin capsule.

      Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.

      Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.

      Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic data after oral administration of 50, 100 or 150 mg of fenobam in groups of healthy individuals.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples will be drawn periodically before and after fenobam/placebo administration for approximately 10 hours (at approximately 30, 60, 120, 180, 240, 300, 360 and 600 minutes) and one more time the next day (day 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of tolerability</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants will be administered a questionnaire regarding side effects at the end of the study day, after administration of a single dose of 50 mg, 100 mg or 150 mg of fenobam, or 150 mg placebo. The questionnaire will be administered again the following day and one week after the study day. Side effects in the fenobam treatment groups will be compared to side effects in the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fenobam 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenobam 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenobam 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenobam</intervention_name>
    <description>Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)</description>
    <arm_group_label>Fenobam 50 mg</arm_group_label>
    <arm_group_label>Fenobam 100 mg</arm_group_label>
    <arm_group_label>Fenobam 150 mg</arm_group_label>
    <other_name>N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo or lactose 150 mg</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. 18-50 yr old

          2. Good general health with no remarkable medical conditions (e.g  liver, kidney, heart,
             or lung failure), BMI&lt;33 and no known drug allergies.

          3. Willing to comply with study guidelines as outlined in protocol

          4. Willing to provide informed consent.

        Exclusion Criteria

          1. Medication use (prescription or non prescription medications, vitamins, herbals,
             dietary and mineral supplements and grapefruit products during or within 14 days
             prior to study participation; excludes contraceptives)

          2. History of addiction to drugs or alcohol (prior or present addiction or treatment for
             addiction)

          3. Pregnant or nursing female

          4. Lactose intolerance

          5. Smokers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Cavallone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>March 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Laura Cavallone</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Fenobam,</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>side effects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
